Gould Stacey Anne, Doods Henri, Lamla Thorsten, Pekcec Anton
Boehringer Ingelheim Pharma GmbH & Co. KG, Div. Research Germany, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Div. Research Germany, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.
Behav Brain Res. 2016 Mar 15;301:142-51. doi: 10.1016/j.bbr.2015.12.019. Epub 2015 Dec 15.
It has recently been suggested that non-reflex behavioral readouts, such as burrowing, may be used to evaluate the efficacy of analgesics in rodent models of pain.
To confirm whether intraplantar Complete Freund's Adjuvant (CFA)-induced pain reliably results in burrowing deficits which can be ameliorated by clinically efficacious analgesics as previously suggested.
Uni- or bilateral intraplantar CFA injections were performed in male Wistar Han rats. The time- and concentration-response of burrowing deficits and the ability of various analgesics to reinstate burrowing performance were studied. An anxiolytic was also tested to evaluate the motivational cue that drives this behavior.
Burrowing deficits were dependent on the concentration of CFA injected, most pronounced 24h after CFA injections and even more pronounced after bilateral compared with unilateral injections. Celecoxib and ibuprofen reversed CFA-induced burrowing deficits whereas indomethacin failed to significantly reinstate burrowing performance. Morphine and tramadol failed to reinstate burrowing performance, but sedation was observed in control rats at doses thought to be efficacious. An antibody directed against the nerve growth factor significantly improved CFA-induced burrowing deficits. Neither gabapentin nor the anxiolytic diazepam reinstated burrowing performance and the opportunity to find shelter did not modify burrowing performance.
Burrowing is an innate behavior reliably exhibited by rats. It is suppressed in a model of inflammatory pain and differently reinstated by clinically efficacious analgesics that lack motor impairing side effects, but not an anxiolytic, suggesting that this assay is suitable for the assessment of analgesic efficacy of novel drugs.
最近有人提出,非反射性行为读数,如打洞行为,可用于评估啮齿动物疼痛模型中镇痛药的疗效。
证实足底注射完全弗氏佐剂(CFA)诱导的疼痛是否确实会导致打洞行为缺陷,以及如先前所述,临床有效的镇痛药是否可改善这种缺陷。
对雄性Wistar Han大鼠进行单侧或双侧足底注射CFA。研究了打洞行为缺陷的时间和浓度反应,以及各种镇痛药恢复打洞行为的能力。还测试了一种抗焦虑药,以评估驱动这种行为的动机线索。
打洞行为缺陷取决于注射的CFA浓度,在注射CFA后24小时最为明显,双侧注射比单侧注射更明显。塞来昔布和布洛芬可逆转CFA诱导的打洞行为缺陷,而吲哚美辛未能显著恢复打洞行为。吗啡和曲马多未能恢复打洞行为,但在认为有效的剂量下,对照大鼠出现了镇静作用。一种针对神经生长因子的抗体显著改善了CFA诱导的打洞行为缺陷。加巴喷丁和抗焦虑药地西泮均未恢复打洞行为,寻找庇护所的机会也未改变打洞行为。
打洞是大鼠可靠表现出的一种先天行为。在炎症性疼痛模型中,这种行为受到抑制,缺乏运动损伤副作用的临床有效镇痛药可不同程度地恢复这种行为,但抗焦虑药则不能,这表明该试验适用于评估新药的镇痛效果。